Published in PLoS Comput Biol on April 28, 2011
Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proc Natl Acad Sci U S A (2014) 2.23
Early immunologic correlates of HIV protection can be identified from computational analysis of complex multivariate T-cell flow cytometry assays. Bioinformatics (2012) 1.46
Modeling the within-host dynamics of HIV infection. BMC Biol (2013) 1.29
Immunological biomarkers predict HIV-1 viral rebound after treatment interruption. Nat Commun (2015) 1.10
Spatial heterogeneity in drug concentrations can facilitate the emergence of resistance to cancer therapy. PLoS Comput Biol (2015) 0.96
Post-treatment control of HIV infection. Proc Natl Acad Sci U S A (2015) 0.90
Modeling antiretroviral drug responses for HIV-1 infected patients using differential equation models. Adv Drug Deliv Rev (2013) 0.89
Modeling the Effects of Vorinostat In Vivo Reveals both Transient and Delayed HIV Transcriptional Activation and Minimal Killing of Latently Infected Cells. PLoS Pathog (2015) 0.86
Computational inference methods for selective sweeps arising in acute HIV infection. Genetics (2013) 0.84
Simple mathematical models do not accurately predict early SIV dynamics. Viruses (2015) 0.76
Stochastic modelling of the eradication of the HIV-1 infection by stimulation of latently infected cells in patients under highly active anti-retroviral therapy. J Math Biol (2016) 0.76
Increased inflammation in sanctuary sites may explain viral blips in HIV infection. IET Syst Biol (2016) 0.75
Virological blips and predictors of post treatment viral control after stopping ART started in Primary HIV infection. J Acquir Immune Defic Syndr (2016) 0.75
Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents. J Virol (2017) 0.75
Backward bifurcations, turning points and rich dynamics in simple disease models. J Math Biol (2016) 0.75
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet (2008) 36.01
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10
Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med (2008) 17.12
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature (1997) 15.49
Decay characteristics of HIV-1-infected compartments during combination therapy. Nature (1997) 13.68
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75
HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med (2009) 8.45
The challenge of finding a cure for HIV infection. Science (2009) 8.41
Immune responses to Listeria monocytogenes. Nat Rev Immunol (2004) 5.91
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med (2010) 5.36
Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA (1999) 4.98
ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog (2007) 4.82
The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med (2002) 4.73
Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A (2009) 4.58
Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol (2000) 4.46
Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet (1999) 4.36
Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA (2005) 4.24
A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol (2003) 4.12
Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA (2001) 3.73
HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A (2008) 3.40
Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med (1998) 3.11
Generation of HIV latency during thymopoiesis. Nat Med (2001) 2.91
Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol (2005) 2.82
Dynamics of HIV infection of CD4+ T cells. Math Biosci (1993) 2.75
The multifactorial nature of HIV-1 latency. Trends Mol Med (2004) 2.68
Production of resistant HIV mutants during antiretroviral therapy. Proc Natl Acad Sci U S A (2000) 2.61
Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol (2009) 2.47
Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr (2004) 2.05
Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA (1998) 1.83
Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. J Infect Dis (2001) 1.67
Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 1.54
Viral blip dynamics during highly active antiretroviral therapy. J Virol (2003) 1.51
Modeling HIV persistence, the latent reservoir, and viral blips. J Theor Biol (2009) 1.49
Prevalence and clinical correlates of HIV viremia ('blips') in patients with previous suppression below the limits of quantification. AIDS (2002) 1.42
Viral and latent reservoir persistence in HIV-1-infected patients on therapy. PLoS Comput Biol (2006) 1.35
Mechanisms of HIV latency: an emerging picture of complexity. Curr HIV/AIDS Rep (2010) 1.33
A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients. J Virol (2005) 1.32
Increased frequency of HIV-1 viral load blip rate observed after switching from Roche Cobas Amplicor to Cobas Taqman assay. J Acquir Immune Defic Syndr (2009) 1.31
Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis (2000) 1.26
Stochastic theory of early viral infection: continuous versus burst production of virions. PLoS Comput Biol (2011) 1.15
The role of antigenic stimulation and cytotoxic T cell activity in regulating the long-term immunopathogenesis of HIV: mechanisms and clinical implications. Proc Biol Sci (2001) 1.14
Pharmaceutical approaches to eradication of persistent HIV infection. Expert Rev Mol Med (2009) 1.13
Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy. J Infect (2005) 1.11
Transient rebounds of low-level viraemia among HIV-infected patients under HAART are not associated with virological or immunological failure. Antivir Ther (2002) 1.10
Opportunistic infection as a cause of transient viremia in chronically infected HIV patients under treatment with HAART. Bull Math Biol (2005) 1.10
Antigen-driven CD4+ T cell and HIV-1 dynamics: residual viral replication under highly active antiretroviral therapy. Proc Natl Acad Sci U S A (1999) 1.08
Optimal drug treatment regimens for HIV depend on adherence. J Theor Biol (2007) 1.08
Quantification of intrinsic residual viral replication in treated HIV-infected patients. Proc Natl Acad Sci U S A (2001) 0.95
Modeling the effects of vaccination on chronically infected HIV-positive patients. J Acquir Immune Defic Syndr (2002) 0.94
Decelerating decay of latently infected cells during prolonged therapy for human immunodeficiency virus type 1 infection. J Virol (2002) 0.92
Enumeration of latently infected CD4+ T cells from HIV-1-infected patients using an HIV-1 antigen ELISPOT assay. J Clin Virol (2004) 0.85
Duration of an intermittent episode of viremia. Bull Math Biol (2005) 0.82
Dependence of T cell antigen recognition on T cell receptor-peptide MHC confinement time. Immunity (2010) 2.82
T cell receptor binding kinetics required for T cell activation depend on the density of cognate ligand on the antigen-presenting cell. Proc Natl Acad Sci U S A (2005) 1.49
Evolution of virulence: interdependence, constraints, and selection using nested models. Theor Popul Biol (2005) 1.37
A hidden Markov model for single particle tracks quantifies dynamic interactions between LFA-1 and the actin cytoskeleton. PLoS Comput Biol (2009) 1.19
Optimizing within-host viral fitness: infected cell lifespan and virion production rate. J Theor Biol (2004) 1.18
A role for rebinding in rapid and reliable T cell responses to antigen. PLoS Comput Biol (2009) 1.11
Mechanical force regulates integrin turnover in Drosophila in vivo. Nat Cell Biol (2012) 1.02
Modeling within-host evolution of HIV: mutation, competition and strain replacement. Bull Math Biol (2007) 0.98
Dynamic regulation of CD45 lateral mobility by the spectrin-ankyrin cytoskeleton of T cells. J Biol Chem (2010) 0.97
Effects of intracellular calcium and actin cytoskeleton on TCR mobility measured by fluorescence recovery. PLoS One (2008) 0.96
Quantification and modeling of tripartite CD2-, CD58FC chimera (alefacept)-, and CD16-mediated cell adhesion. J Biol Chem (2007) 0.94
An age-structured model of hiv infection that allows for variations in the production rate of viral particles and the death rate of productively infected cells. Math Biosci Eng (2004) 0.93
Analysis of serial engagement and peptide-MHC transport in T cell receptor microclusters. Biophys J (2008) 0.93
Analysis of membrane-localized binding kinetics with FRAP. Eur Biophys J (2008) 0.91
Vaccination against 2009 pandemic H1N1 in a population dynamical model of Vancouver, Canada: timing is everything. BMC Public Health (2011) 0.91
The space and time frames of T cell activation at the immunological synapse. FEBS Lett (2010) 0.89
Analysis of peptide/MHC-induced TCR downregulation: deciphering the triggering kinetics. Cell Biochem Biophys (2006) 0.86
Mechanical modulation of receptor-ligand interactions at cell-cell interfaces. Biophys J (2012) 0.86
Improving parameter estimation for cell surface FRAP data. J Biochem Biophys Methods (2007) 0.83
Kinetic proofreading model. Adv Exp Med Biol (2008) 0.82
Asymptotic analysis of first passage time problems inspired by ecology. Bull Math Biol (2014) 0.81
Modeling effect of a γ-secretase inhibitor on amyloid-β dynamics reveals significant role of an amyloid clearance mechanism. Bull Math Biol (2010) 0.81
A theoretical and experimental study of competition between solution and surface receptors for ligand in a Biacore flow cell. Bull Math Biol (2006) 0.80
Erratum: Toll-like receptor ligands sensitize B-cell receptor signalling by reducing actin-dependent spatial confinement of the receptor. Nat Commun (2015) 0.76
A biophysical model of cell adhesion mediated by immunoadhesin drugs and antibodies. PLoS One (2011) 0.75